Neurological disorder

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results

Retrieved on: 
星期四, 五月 9, 2024
Research, FDA, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Investment, Webcast, IND, WFS1, TDP43, AMX0035, Diabetes, Samuel, CSF, Biomarker, Astellas Pharma, Disclosure, Brain, Food, Amylyx Pharmaceuticals, Endoplasmic reticulum, Health Canada, Tauopathy, ALS, Eli Lilly and Company, FCCP, Medication, Merck, Cerebrospinal fluid, Safety, PB, Neurological disorder, Genetic linkage, Week, Wolfram syndrome, C-peptide, DSM-IV codes, Drug development, Clinical trial, Walking, Division, MD, Patient, Disease, Regulation Fair Disclosure, Principal, Regulation, PGIC, Metabolism, Interim, FACP, Pharmaceutical industry

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the first quarter ended March 31, 2024.
  • This decision was informed by topline PHOENIX trial results, engagement with regulatory authorities, and discussions with the ALS community.
  • Amylyx anticipates reporting topline data from all 12 participants at Week 24 in the fall of 2024.
  • Amylyx’ management team will host a conference call and webcast today, May 9, 2024, at 8:00 a.m.

2024 World Brain Day Dedicated to Brain Health and Prevention

Retrieved on: 
星期二, 五月 7, 2024
Public, World government, Myenteric plexus, Mayo Clinic, Stroke, Parkinson's disease, WHO, Social media, Neurological disorder, World Health Organization, Policy, Risk, WBD, Guest, Health care, MD, Life, Alzheimer's disease, Culture, Exercise, Smoking cessation, Encephalitis, Society, Diet, Meningitis, DSM-IV codes, Movement, Epilepsy, Multiple sclerosis, Dementia, Sleep, WFN

LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22.

Key Points: 
  • LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22.
  • "This World Brain Day is a chance for us to unite and advocate for our present and future," says Prof. Tissa Wijeratne, World Brain Day Co-Chair.
  • "As we approach World Brain Day 2024, let's come together to support brain health and prevention.
  • Mark your calendars for July 22—a day dedicated to celebrating brain health and promoting prevention.

2024 World Brain Day Dedicated to Brain Health and Prevention

Retrieved on: 
星期二, 五月 7, 2024
Public, World government, Myenteric plexus, Mayo Clinic, Stroke, Parkinson's disease, WHO, Social media, Neurological disorder, World Health Organization, Policy, Risk, WBD, Guest, Health care, MD, Life, Alzheimer's disease, Culture, Exercise, Smoking cessation, Encephalitis, Society, Diet, Meningitis, DSM-IV codes, Movement, Epilepsy, Multiple sclerosis, Dementia, Sleep, WFN

LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22.

Key Points: 
  • LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22.
  • "This World Brain Day is a chance for us to unite and advocate for our present and future," says Prof. Tissa Wijeratne, World Brain Day Co-Chair.
  • "As we approach World Brain Day 2024, let's come together to support brain health and prevention.
  • Mark your calendars for July 22—a day dedicated to celebrating brain health and promoting prevention.

THE BETA GROUP: Do Race Horses Have to be Killed for a Fractured Leg?

Retrieved on: 
星期五, 五月 3, 2024
Leg, Horse, Component, System, Hope, Neurological disorder, Rib, History, Anatomy, Silicon, Spinal cord, Athlete, Memory, Tell

One year ago, 12 horses died just before and after, sparking outrage in the press: https://www.nytimes.com/search?query=Kentucky+derby+horse+deaths

Key Points: 
  • One year ago, 12 horses died just before and after, sparking outrage in the press: https://www.nytimes.com/search?query=Kentucky+derby+horse+deaths
    Why is it that human athletes can be healed for a fractured leg, but equine athletes are often times "euthanized"?
  • Obviously, no veterinarian wants to kill a horse for a fractured leg!
  • But these outcomes are fueling the fire for Animal Rights groups to end horse racing.
  • Horses, however, have a unique anatomy and that makes it very challenging if not impossible to rehabilitate horses with fractured legs.

Elara Caring Partners with Constant Therapy to Deliver First AI-Driven Speech-Language and Cognitive Therapy at Scale

Retrieved on: 
星期三, 四月 17, 2024
Brain, Stroke, Neurological disorder, Health, Population health, Partnership, Dementia, Patient, Caregiver, DSM-IV codes, Constant, Pharmaceutical industry

Insights available through Constant Therapy’s enterprise platform complement Elara Caring’s use of population health data, improving care plans for patients with neurological disorders.

Key Points: 
  • Insights available through Constant Therapy’s enterprise platform complement Elara Caring’s use of population health data, improving care plans for patients with neurological disorders.
  • With the partnership, Elara clinicians can now deliver a highly-personalized course of therapeutic exercises – and measure patient progress – to best meet the needs of patients recovering from conditions such as stroke, brain injury or dementia.
  • Simultaneously, Elara patients are given unlimited access to the Constant Therapy mobile app – allowing them to maintain engagement with their therapy program outside of their scheduled clinical visits.
  • “Elara Caring is well recognized for its use of advanced technology and data insights that help proactively treat and monitor patients,” said Mark Salley, VP of Innovations and Rehab Solutions, Elara Caring.

GLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORING

Retrieved on: 
星期二, 四月 16, 2024
Pain, Electrode, SCS, Epidural space, Neurological disorder, Animal, Diabetes, CGM, Electricity, Doctor of Philosophy, Blood, PDN, Patient, Spinal cord stimulator, Spinal cord, Glucose, Hypoesthesia, Quality of life, Medical device

Rutherford, NJ, April 16, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it is expanding its glucose monitoring technology to include measuring glucose in the epidural space. A continuous glucose monitoring system that takes readings in the spinal epidural space may be integrated with existing treatments for patients with Painful Diabetic Neuropathy (PDN).

Key Points: 
  • A continuous glucose monitoring system that takes readings in the spinal epidural space may be integrated with existing treatments for patients with Painful Diabetic Neuropathy (PDN).
  • Combining SCS and continuous glucose monitoring (CGM) could provide several possible advantages, such as simplifying device management for those patients.
  • This is the second application of Glucotrack’s technology for implantable continuous glucose monitoring, in addition to its development of a long-term Continuous Blood Glucose Monitoring (CBGM) system.
  • The results demonstrated the Glucotrack epidural glucose values closely tracked both the blood glucose and subcutaneous CGM values.

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting

Retrieved on: 
星期一, 四月 22, 2024
Research, Neurology, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Brain, MECP2, Safety, Neurological disorder, Rett syndrome, Cell, Patient, Gene, Society, DSM-IV codes, Inc., Clinical trial, Annual general meeting, Syndrome, Pharmaceutical industry

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be presented at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting.

Key Points: 
  • Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be presented at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting.
  • The data show that the NGN-401 gene therapy candidate has been generally well-tolerated, and there have been no treatment-emergent or procedure-related serious adverse events or signs of MeCP2 overexpression-related toxicity observed in any patient, including a patient with a mild variant predicted to result in residual MeCP2 function.
  • “Rett syndrome is a complex neurological disorder with a narrow therapeutic window, and conventional gene therapy approaches have been unable to provide therapeutic protein levels without detrimental overexpression.
  • Therefore, we believe it is important to share this safety update at the ASGCT Meeting, in advance of our expected fourth quarter 2024 interim efficacy read-out, as we have multiple months of data from three patients showing NGN-401 has been generally well-tolerated.”
    Title: Preliminary Safety Results from the Ph1/2 study of NGN-401, a Novel Regulated Gene Therapy for Rett Syndrome

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Retrieved on: 
星期二, 四月 23, 2024
RSRT, Neurological disorder, Health, Rett syndrome, Respiratory rate, Partnership, Research, ECG, Heart rate, Speech, Therapy, Patient, Data collection, Caregiver, Posture, Drug development, Biomarker, Genetic disorder, Sleep, Frasier, Dysautonomia, Medical device

CAMPBELL, Calif., April 23, 2024 /PRNewswire/ -- Vivalink, a leading provider of digital healthcare solutions, announces its collaboration with the Rett Syndrome Research Trust (RSRT) to advance research into Rett syndrome, a rare neurological disorder. As part of this partnership, Vivalink is providing its Multi-Vital ECG wearable technology and data services for heart rate and oxygen saturation monitoring to support RSRT's new VIBRANT study, aimed at assessing autonomic dysfunction in individuals with Rett syndrome.

Key Points: 
  • CAMPBELL, Calif., April 23, 2024 /PRNewswire/ -- Vivalink , a leading provider of digital healthcare solutions, announces its collaboration with the Rett Syndrome Research Trust (RSRT) to advance research into Rett syndrome, a rare neurological disorder.
  • Vivalink's advanced wearable devices provide an important opportunity to expedite drug development in the pursuit of a cure for Rett Syndrome.
  • "We are excited to partner with the Rett Syndrome Research Trust in their pioneering study," said Aaron Timm, Chief Commercial Officer at Vivalink.
  • "We hope to empower researchers with the tools they need to make meaningful advancements in understanding and treating Rett syndrome."

Intranasal Delivery of shRNA Edits to Silence 5-HT2A Receptor Shows Promise in Enhancing Memory and Alleviating Anxiety

Retrieved on: 
星期四, 三月 21, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Genetics, Clinical Trials, Depression, Brain, Dementia, Rat, BBB, Memory, Central nervous system, Public, RNA, Mouse, Traffic barrier, Anxiety, Translational Psychiatry, MCI, Neurological disorder, DSM-IV codes, HTR2A, Intrinsic termination, Therapy, Optimism, Cas9, Vaccine

In a groundbreaking study, they successfully used a non-invasive intranasal delivery platform to administer short-hairpin RNA (shRNA) that targets the 5-HT2A receptor resulting in long-lasting improvements in memory and reduced anxiety in animal models.

Key Points: 
  • In a groundbreaking study, they successfully used a non-invasive intranasal delivery platform to administer short-hairpin RNA (shRNA) that targets the 5-HT2A receptor resulting in long-lasting improvements in memory and reduced anxiety in animal models.
  • Neurological disorders such as Mild Cognitive Impairment (MCI), depression, and anxiety disorders pose significant challenges to public health worldwide.
  • In this study, the researchers designed shRNA sequences to specifically target and silence the human HTR2A gene, which is associated with anxiety and memory.
  • The ability to bypass the blood-brain barrier using intranasal delivery opens up new avenues for precision-based therapeutics in neurological disorders."

FDA Approves Nonsteroidal Treatment for Duchenne Muscular Dystrophy

Retrieved on: 
星期四, 三月 21, 2024
Research, HDAC, Neurological disorder, Walking, Abdominal pain, Dietary supplement, Risk, Inflammation, Patient, QT interval, Public, Animal, Duchenne muscular dystrophy, Diarrhea, Food, Human services, Platelet, Facial muscles, Life expectancy, Heated tobacco product, Fever, Atrophy, Safety, Division, NSAA, Muscle weakness, Cosmetics, Vaccine, Multimedia, FDA, DMD, Muscular dystrophy, Triglyceride, Pharmaceutical industry

SILVER SPRING, Md., March 21, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older.

Key Points: 
  • SILVER SPRING, Md., March 21, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older.
  • Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD.
  • "This approval provides another treatment option to help reduce the burden of this progressive, devastating disease for individuals impacted by DMD regardless of genetic mutation."
  • DMD is the most common childhood form of muscular dystrophy and typically affects males.